Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Recruiting
Observational Study
Early Breast Cancer
Ductal Breast Carcinoma In Situ
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 20 – 85
- Sex
- Female
- Study type
- Observational
- Participants needed
- 315 (estimated)
- Sponsor
- National Taiwan University Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
* Patients undergoing breast-conserving surgery
* Age ≥ 20 years
* Karnofsky Performance Status (KPS) ≥70%
* Life expectancy ≥ 5 years
* Adequate renal a…
Contacts